Preferred Label : Dabrafenib Mesylate;

NCIt synonyms : Dabrafenib Methanesulfonate; GSK2118436 Methane Sulfonate Salt;

NCIt definition : The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.;

UNII : B6DC89I63E;

InChIKey : YKGMKSIHIVVYKY-UHFFFAOYSA-N;

CAS number : 1195768-06-9;

Drug name : Tafinlar;

Molecule name : GSK2118436B;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/finlee
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dabrafenib
dabrafenib
dabrafenib
drug approval
orphan drug production
glioma
malignant glioma
infant
child
antineoplastic combined chemotherapy protocols
Dabrafenib/Trametinib Regimen
Childhood Low Grade Glioma
Childhood Malignant Glioma
europe
Dabrafenib Mesylate
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
BRAF V600E Mutation Present
administration, oral
BRAF Inhibitor
proto-oncogene proteins b-raf
drug interactions
drug evaluation, preclinical

---
Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.